ArticleScientific reports2025
Proinflammatory markers in women with type 1 diabetes and polycystic ovary syndrome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The frequency of polycystic ovary syndrome (PCOS) appears to be higher in women living with type 1 diabetes (T1D). Both diseases are characterized by a mild chronic inflammatory state. The proinflammatory protein profile in this population has not been fully evaluated. We conducted a cross-sectional, exploratory study in patients at the T1D Clinic from a tertiary referral hospital in Mexico. Using stored samples from a previous cohort, we categorized patients with T1D with or without PCOS, overweight/obesity, and metabolic syndrome (MS). C-reactive protein (CRP), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-a) levels were quantified and compared among the groups. Thirty-seven patients were analyzed. IL-6 levels were greater in the groups with T1D and overweight or obesity than in the group with a normal body mass index (p = 0.003) and were greater in the group with T1D and MS than in the group with T1D without MS (p = 0.029). No differences were observed among patients with T1D with or without PCOS. Post-hoc power analysis indicated high power (> 95%) to detect clinically relevant differences in CRP and IL-6, but low power (26%) for TNF-a. In this exploratory study of women with T1D, obesity and other components of MS appeared more important determinants of inflammation than PCOS, probably because of the different pathophysiology of PCOS in these patients and the dominant inflammatory effect of adiposity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.